Cognition Therapeutics Receives $6.6M from NIA to Study Elayta Synaptoprotective Mechanism of Action in Alzheimer's

Cognition Therapeutics, Inc., announced on 5/22/18 the receipt of two multi-year grants from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) totaling $6.6 million. These awards will fund two clinical studies of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, which are primarily designed to probe Elayta’s unique synaptoprotective mechanism of action.